LIXTE Biotechnology Holdings, Inc.

LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies including cytotoxic drugs, radiation, and immune checkpoint blockers.